Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
Abstract The optimal adjuvant endocrine therapy for HR-positive/HER2-positive breast cancer patients is unknown. We included in this analysis 784 patients with HR-positive/HER2-positive BC from the randomized ShortHER trial of adjuvant trastuzumab (1 year vs 9 weeks) + chemotherapy. At a median foll...
| Κύριοι συγγραφείς: | , , , , , , , , |
|---|---|
| Μορφή: | Άρθρο |
| Γλώσσα: | English |
| Έκδοση: |
Nature Portfolio
2023-02-01
|
| Σειρά: | npj Breast Cancer |
| Διαθέσιμο Online: | https://doi.org/10.1038/s41523-023-00509-2 |